Novo Holdings, controlling shareholder in drugmaker Novo Nordisk, and Gurnet Point Capital on Thursday closed their acquisition of biopharmaceutical company Paratek Pharmaceuticals in a deal worth $462 million, Novo Holdings said.
The acquisition of Paratek Pharmaceuticals, which was announced in early June, is Novo Holdings’ largest individual investment in antimicrobial resistance therapies to date, it said.
Novo Holdings, which controls 76% of the votes in Denmark’s Novo Nordisk last week announced a major investment in a new energy transition fund, as it is looking to expand its portfolio beyond health.
Source: Reuters.com